Drug Profile
LY 3113593
Alternative Names: LY3113593Latest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Bone morphogenetic protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 29 Sep 2021 Discontinued - Phase-II for Anaemia in USA (Parenteral) (Eli Lilly and Company pipeline, September 2021)
- 22 Jun 2016 Eli Lilly completes a phase I trial for Anaemia (In patients with chronic kidney disease) in USA (IV) (NCT02604160)
- 25 Jan 2016 Phase-II clinical trials in Anaemia in USA (Parenteral) before January 2016